{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:19:59Z","timestamp":1741238399681,"version":"3.38.0"},"reference-count":25,"publisher":"JLE","issue":"7","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.nephro.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T05:27:53Z","timestamp":1348550873000},"page":"527-533","source":"Crossref","is-referenced-by-count":1,"title":["Efficacit\u00e9 du cinacalcet en pratique clinique chez les patients dialys\u00e9s pr\u00e9sentant une hyperparathyro\u00efdie secondaire\u00a0: observatoire ECHO \u2013 Exp\u00e9rience fran\u00e7aise"],"prefix":"10.1684","volume":"8","author":[{"given":"P.","family":"Ure\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Fouque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Touam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"R\u00e9glier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2012.05.002_bib0005","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2012.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.01060308","article-title":"Consistent control of mineral and bone disorder in incident hemodialysis patients","volume":"3","author":"Danese","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2012.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2004.12.011","article-title":"Secondary hyperparathyroidism: review of the disease and its treatment","volume":"26","author":"De Francisco","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.nephro.2012.05.002_bib0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","article-title":"Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product","volume":"23","author":"Moe","year":"2003","journal-title":"Am J Nephrol"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.nephro.2012.05.002_bib0025","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2012.05.002_bib0030","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.nephro.2012.05.002_bib0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","article-title":"Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practices patterns study (DOPPS)","volume":"44","author":"Young","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2012.05.002_bib0040","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques de Mimpara\u00ae. http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/000570\/WC500028900.pdf."},{"key":"10.1016\/j.nephro.2012.05.002_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2012.05.002_bib0050","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","article-title":"Cinacalcet and achievement of the NKF\/K-DOQI recommended arget values for bone and mineral metabolism in real-world clinical practice \u2014 the ECHO observational study","volume":"24","author":"Ure\u00f1a","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2012.05.002_bib0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5414\/CNP74198","article-title":"7\u201creal-word\u201d use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study","volume":"74","author":"Vervloet","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2012.05.002_bib0060","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/ndt\/gfq641","article-title":"Effectiveness of cinacalcet inpatients with recurrent\/persistant secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study","volume":"26","author":"Zitt","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2012.05.002_bib0065","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1523-1755.2005.00517.x","article-title":"First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl","volume":"68","author":"Martin","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2012.05.002_bib0070","unstructured":"Couchoud C, Stengel B, Jacquelinet C. Registre REIN. Rapport 2005. http:\/\/www.soc-nephrologie.org\/REIN\/documents.htm."},{"key":"10.1016\/j.nephro.2012.05.002_bib0075","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2012.05.002_bib0080","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, CaxPO4\u00a0product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2012.05.002_bib0085","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysi","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2012.05.002_bib0090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2012.05.002_bib0095","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2215\/CJN.05241008","article-title":"Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004\u00a0through 2006","volume":"4","author":"St Peter","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2012.05.002_bib0100","doi-asserted-by":"crossref","first-page":"c41","DOI":"10.1159\/000212102","article-title":"Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet","volume":"112","author":"Wilkie","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nephro.2012.05.002_bib0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2012.05.002_bib0110","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/ndt\/gfp762","article-title":"Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients","volume":"25","author":"Floege","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2012.05.002_bib0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2012.05.002_bib0120","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2012.05.002_bib0125","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","article-title":"Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview","volume":"2","author":"Chertow","year":"2007","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725512000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725512000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2012.05.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:33:25Z","timestamp":1741185205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725512000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1769725512000958"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2012.05.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}